Roche used the 2023 European Society for Medical Oncology Congress in Madrid to present pivotal lung cancer data. The results came from ALINA, a global Phase III study of Alecensa after surgery for early lung cancer. Investigators compared the targeted medicine with platinum-based chemotherapy in patients carrying an anaplastic lymphoma kinase alteration. Roche reported a 76% reduction in the risk of recurrence or death among patients with stage II to IIIA disease. The presentation drew attention because recurrence remains common after apparently successful surgery for this cancer. It also moved precision treatment into an earlier setting, before metastatic disease develops.<\/p>\n\n\n\n
Non-small cell lung cancer accounts for about 85% of all lung cancers, making treatment advances broadly important. Surgery can cure some early-stage cases, but hidden cancer cells may remain and later seed new tumors. Doctors therefore recommend adjuvant therapy for many patients whose tumors carry a substantial recurrence risk. Platinum chemotherapy has long served that role, although its benefits remain limited and toxicity can complicate recovery. ALINA tested whether continuous ALK inhibition could control residual disease more effectively than a short chemotherapy course. That question reflected a wider oncology shift toward matching postoperative treatment with each tumor’s biological driver.<\/p>\n\n\n\n
The trial enrolled 257 people with completely resected ALK-positive non-small cell lung cancer. Eligible cancers ranged from stage IB to IIIA under the staging system used by investigators. Stage IB tumors needed to measure at least four centimeters, while later stages involved greater local spread. Researchers randomly assigned patients to oral Alecensa or standard platinum chemotherapy after complete tumor removal. The Alecensa group received 600 milligrams twice daily for two years, unless disease returned or toxicity intervened. The comparison group received four chemotherapy cycles, following established postoperative practice. Independent committees monitored the study, while investigators assessed disease-free survival using prespecified statistical rules.<\/p>\n\n\n\n
ALINA met its primary endpoint in patients with stage II through IIIA disease. The hazard ratio was 0.24, corresponding to the reported 76% relative risk reduction. After two years, 93.8% of Alecensa-treated patients remained alive without recurrence in that main analysis. The comparable figure reached 63.0% among patients assigned chemotherapy. Results remained consistent across the broader stage IB through IIIA population, supporting the central finding. Median disease-free survival was not reached with Alecensa when Roche presented the Madrid data. These percentages describe time without recurrence, however, and do not yet prove that patients lived longer overall. That distinction became important as clinicians evaluated the strength and maturity of the evidence.<\/p>\n\n\n\n
Brain metastases create a serious challenge in ALK-positive lung cancer, even when doctors initially remove the chest tumor. Alecensa was designed to reach the central nervous system and block ALK-driven cancer signaling. In ALINA, the medicine reduced the risk of recurrence within the brain or death by 78%. That analysis produced a hazard ratio of 0.22, strengthening the broader disease-free survival result. Preventing brain relapse can preserve neurological function and may delay radiation, surgery, or additional systemic treatment. Nevertheless, longer observation must show whether this control translates into a durable overall survival benefit. The brain findings therefore added clinical weight without eliminating uncertainty about the trial’s final outcomes.<\/p>\n\n\n\n
Roche said Alecensa’s safety profile matched earlier experience, and investigators identified no unexpected safety signals. Patients took Alecensa much longer than chemotherapy, which complicates simple comparisons between total side effects. Grade three or four adverse events occurred in roughly 30% of each treatment group. Common Alecensa effects included increased creatine kinase, constipation, and elevated liver enzymes. Chemotherapy more often caused familiar short-term problems, including nausea, anemia, and reduced appetite. Doctors can manage many targeted-treatment effects through monitoring, temporary interruptions, dose reductions, or supportive care. However, two years of therapy requires adherence and regular checks for muscle, liver, and heart complications. Those practical demands influence real-world decisions, especially after patients have already recovered from major surgery.<\/p>\n\n\n\n
Alecensa, also called alectinib, selectively inhibits abnormal ALK proteins that drive tumor growth. ALK rearrangements occur in only a small share of non-small cell lung cancers. They appear more frequently in younger patients and people with little or no smoking history. Testing remains essential, because symptoms and scans cannot reliably identify the molecular alteration. Before ALINA, regulators had widely approved Alecensa for advanced ALK-positive lung cancer. Studies in metastatic disease had already demonstrated strong systemic activity and meaningful control inside the brain. Roche and its Chugai unit developed the medicine, which became a major product within Roche’s oncology portfolio. ALINA asked whether those established properties could prevent relapse when doctors treated patients soon after surgery.<\/p>\n\n\n\n
Overall survival data remained immature at the Madrid presentation, because relatively few patients had died. Investigators planned continued follow-up to measure survival, late recurrences, and long-term adverse effects. They also needed to understand outcomes after relapse, including responses to later ALK inhibitors. ALINA compared Alecensa directly with chemotherapy, rather than testing the treatments sequentially or together. Consequently, the trial could not determine whether chemotherapy before Alecensa would add further benefit. Treatment duration also raised questions, since the study prescribed two years rather than indefinite therapy. Future research could examine different durations and identify which patients face the greatest residual risk. Those gaps did not erase the result, but they shaped balanced discussions with patients.<\/p>\n\n\n\n
Roche said the findings would support submissions to health authorities worldwide. The United States Food and Drug Administration later approved adjuvant Alecensa in April 2024, based on ALINA. That decision covered patients with ALK-positive non-small cell lung cancer following tumor resection. Regulatory review translates trial evidence into prescribing requirements, including validated testing for the ALK alteration. Pathologists therefore play an early role by analyzing resected tumors before clinicians select postoperative therapy. Broader molecular testing can also uncover other actionable drivers and prevent poorly matched treatment choices. Cost, access, monitoring, and local reimbursement policies still affect whether eligible patients receive targeted therapy. The Madrid results thus carried implications beyond one medicine, reinforcing biomarker-led care after surgery.<\/p>\n\n\n\n
ALINA gave Roche a decisive result and offered clinicians a new strategy against recurrence. Its magnitude versus chemotherapy made the Madrid presentation one of the conference’s notable lung cancer updates. Yet responsible interpretation separates disease-free survival from proven overall survival and recognizes ongoing follow-up. For eligible patients, the evidence supports ALK testing and discussions about benefits, risks, and treatment duration. The study ultimately showed how molecularly targeted therapy can reshape care before metastatic disease appears.<\/p>\n","protected":false},"excerpt":{"rendered":"
Roche brings ALINA findings to Madrid Roche used the 2023 European Society for Medical Oncology Congress in Madrid to present pivotal lung cancer data. The results came from ALINA, a global Phase III study of Alecensa after surgery for early lung cancer. Investigators compared the targeted medicine with platinum-based chemotherapy in patients carrying an anaplastic […]<\/p>\n","protected":false},"author":2,"featured_media":10843,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"apple_news_cover_media_provider":"image","apple_news_coverimage":0,"apple_news_coverimage_caption":"","apple_news_cover_video_id":0,"apple_news_cover_video_url":"","apple_news_cover_embedwebvideo_url":"","apple_news_is_hidden":"","apple_news_is_paid":"","apple_news_is_preview":"","apple_news_is_sponsored":"","apple_news_maturity_rating":"","apple_news_metadata":"\"\"","apple_news_pullquote":"","apple_news_pullquote_position":"","apple_news_slug":"","apple_news_sections":[],"apple_news_suppress_video_url":false,"apple_news_use_image_component":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_hide_featured_image":false,"_jetpack_featured_image_duplicate_dismissed":0,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false,"_ppma_block_editor_authors":""},"categories":[1],"tags":[],"ppma_author":[356],"class_list":["post-10842","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"apple_news_notices":[],"yoast_head":"\n